GCM
ELV icon

Genus Capital Management’s Elevance Health ELV Stock Holding History

Genus Capital Management’s Portfolio ELV Stock Details ELV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-760
Closed -$331K – 191
2025
Q1 		$331K Buy
+760
New +$305K 0.05% 155
2024
Q2 		– Sell
-5,484
Closed -$2.9M – 254
2024
Q1 		$2.84M Buy
+5,484
New +$2.73M 0.37% 93
2023
Q4 		– Sell
-3,418
Closed -$1.58M – 248
2023
Q3 		$1.49M Buy
3,418
+95
+3% +$43.1K 0.23% 111
2023
Q2 		$1.48M Buy
+3,323
New +$1.53M 0.22% 115

Other funds holding ELV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Genus Capital Management's ELV Position: Q2 2025 in Review

Genus Capital Management sold out of Elevance Health (ELV) in Q2 2025, closing a stake of 760 shares — an estimated $331K sold.

Genus Capital Management first reported a position in ELV in Q2 2023 and held it in 4 quarters. The position peaked at $2.84M in Q1 2024. 1,589 funds tracked by Wall St. Rank hold ELV as of Q2 2025.

  • Genus Capital Management reported no remaining Elevance Health position as of Q2 2025 after selling out during the quarter.
  • Genus Capital Management sold 760 Elevance Health shares in Q2 2025, an estimated $331K.
  • Genus Capital Management first reported a position in Elevance Health in Q2 2023 and held it in 4 quarters.
  • Genus Capital Management's Elevance Health position peaked at $2.84M in Q1 2024.
  • 1,589 funds tracked by Wall St. Rank held Elevance Health as of Q2 2025.

Based on Genus Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.